risedronic acid has been researched along with anastrozole in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y | 1 |
| Cuzick, J | 1 |
| Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C | 1 |
| Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N | 1 |
| Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Barlow, DH; Clack, G; Eastell, R; Makris, A; Van Poznak, C | 1 |
| Blake, GM; Coleman, R; Cuzick, J; Dowsett, M; Eastell, R; Forbes, JF; Gossiel, F; Howell, A; Patel, R; Sestak, I; Singh, S | 1 |
| Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I | 1 |
1 review(s) available for risedronic acid and anastrozole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for risedronic acid and anastrozole
| Article | Year |
|---|---|
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Prognosis; Risedronic Acid; Survival Rate; Treatment Outcome; Triazoles | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Therapy, Combination; Dyspepsia; Etidronic Acid; Female; Humans; Middle Aged; Nausea; Nitriles; Osteoporosis, Postmenopausal; Patient Dropouts; Prospective Studies; Risedronic Acid; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2010 |
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cholesterol, HDL; Cholesterol, LDL; Etidronic Acid; Female; Humans; Lipids; Middle Aged; Nitriles; Risedronic Acid; Treatment Outcome; Triazoles; Triglycerides | 2012 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Prognosis; Risedronic Acid; Triazoles | 2014 |
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Fractures, Bone; Humans; Middle Aged; Peptide Fragments; Placebos; Procollagen; Risedronic Acid; Risk Factors | 2019 |
4 other study(ies) available for risedronic acid and anastrozole
| Article | Year |
|---|---|
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Interactions; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Risedronic Acid; Triazoles | 2007 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Triazoles | 2008 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Calcium Carbonate; Cohort Studies; Combined Modality Therapy; Dietary Supplements; Etidronic Acid; Female; Follow-Up Studies; Humans; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Severity of Illness Index; Triazoles; Vitamin D | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Outcome and Process Assessment, Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Time Factors; Triazoles | 2012 |